Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A

K. A. Marr, R. Hachem, G. Papanicolaou, J. Somani, J. M. Arduino, C. J. Lipka, A. L. Ngai, N. Kartsonis, J. Chodakewitz, Carole A. Sable

Research output: Contribution to journalReview articlepeer-review

Abstract

Background. Mild, transient alanine aminotransferase (ALT) elevations were seen in Phase I studies of caspofungin and cyclosporin A (CsA). Methods. We conducted a retrospective chart review at four sites to characterize the hepatic safety in patients receiving ≥1 day of both drugs over a 20-month period. Investigators assessed reasons for discontinuing concomitant therapy and the presence/etiology of any hepatotoxicity. Results. Forty patients receiving concomitant therapy for 1-290 days (median 17.5 days) were identified. Although common, liver enzyme abnormalities were frequently attributed to other comorbidities or medications. ALT and/or aspartate aminotransferase (AST) elevations occurred in 14 patients (35%). Five had ASTelevations at least possibly related to caspofungin/CsA, but none were >3.6 times the normal upper limit. No ALTelevations were related to caspofungin/CsA. Two of 4 patients had discontinuation of therapy because of hepatotoxicity possibly related to caspofungin/CsA. No serious adverse events occurred because of caspofungin. Conclusions. These data do not suggest a significant risk of clinically relevant hepatotoxicity with concomitant caspofungin/CsA.

Original languageEnglish (US)
Pages (from-to)110-116
Number of pages7
JournalTransplant Infectious Disease
Volume6
Issue number3
DOIs
StatePublished - Sep 1 2004
Externally publishedYes

Keywords

  • Caspofungin
  • Cyclosporin A
  • Hematopoietic stem cell transplantation
  • Hepatotoxicity

ASJC Scopus subject areas

  • Infectious Diseases
  • Transplantation

Fingerprint Dive into the research topics of 'Retrospective study of the hepatic safety profile of patients concomitantly treated with caspofungin and cyclosporin A'. Together they form a unique fingerprint.

Cite this